ABSTRACT
Objective ICD codes are commonly used to filter patient cohorts but may not accurately reflect disease presence. Furthermore, many health problems are recorded in unstructured clinical notes, complicating cohort discovery from EHR data. Existing computed phenotyping methods have limitations in identifying evolving disease patterns and incomplete modeling. This study explores the potential of LLMs, by evaluating GPT-4o’s type II diabetes mellitus (T2DM) phenotyping ability using Retrieval-Augmented Generation (RAG).
Methods A RAG system was built, leveraging 275 patients’ entire notes. We performed total 336 experiments to study the sensitivity of RAG to various chunk sizes, the number of chunks, and prompts across seven embedding models. Then the effectiveness of GPT-4o in T2DM phenotyping was assessed using optimized RAG configurations, comparing with ICD code and PheNorm phenotype performance. Token usage was also evaluated.
Results The results show that GPT-4o with optimized RAG significantly outperformed ICD-10 and PheNorm in sensitivity, NPV, and F1, although PPV and specificity need improvement. When used with general embedding models or a zero-shot prompt, the results showed better sensitivity, NPV, and F1-scores, while domain-specific models and a few-shot prompt excelled in specificity and PPV. Furthermore, RAG optimization allowed lower-ranked embedding models achieve reliable performance. Gte-Qwen2-1.5B-instruct and GatorTronS provided the highest performance in specific evaluation metrics at a substantially lower cost.
Conclusion Optimized RAG configurations significantly enhanced key performance metrics compared to existing methods. This study provides valuable insights into optimal configurations and cost-effective embedding model choices, while identifying limitations such as ranking issues and contextual misinterpretation by LLM.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of Mass General Brigham gave approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Revised Tables for better representation Corrected one error in the dimension size column in Table 3
Data Availability
All shareable data produced in the present work are contained in the manuscript.
